



Current as of June 22, 2026

Author Index

#

19S proteasome	B072
3D microenvironment model	A091

A

anti-PD-1	B055
Accelerated Approval	B033
ACR-2316	A082
Acute leukemia (AML)	B079
acute myeloid leukemia	B085
ADC	A002, A010
ADC Payload, Drug Linkers, ADC associated Toxicity	A001
Agentic, gene identification, knowledge graph	A022
AI	A086
AI/ML, Cholangiocarcinoma, RNA therapeutics	A033
AI-drug discovery	A024
AKT inhibitor	A090
AML, Acute Myeloid Leukemia, Relapsed/Refractory	A018
Androgen Receptor	IA02, B077
Antibody Drug Conjugate	A007
Antibody-drug conjugate	A003
Antibody-Drug Conjugate	A013, A016
Antibody-Drug Conjugates	A014
Antibody–drug conjugates (ADCs)	A011
anti-microtubule therapy	A066
Antineoplastic agents	B029
AP-232	B074
AP3 biological SAR	A082
Apoptosis	B023
Apoptosis, Target, toxicity	A080
AR	B040
ARID, VHL, CRBN.	IA04
ARID1B, Degradar, SWI/SNF	IA04



AACR DRUG DISCOVERY AND DEVELOPMENT (AACR D3)

July 21-24, 2026 | Boston, MA

AACR
American Association
for Cancer Research*

25090336

Artesunate derivatives	B076
artificial intelligence	A023
Artificial intelligence	A027
Artificial Intelligence	A036
Asparaginase	B091
ATM BRCA1 BRCA2	A003
ATPases	B072
ATR inhibition, High-grade serous ovarian cancer	B092
ATR inhibitor	A003
Australia	A056
Autoimmune diseases	B061
Autophagy	B073
Axitinib	B008

B

Basal-like breast cancer	B065
b-catenin	B005
biguanide	A077
biliary tract cancer	B037
Bioavailability	A052
bioinformatics	A032
Biomarker	A035
biomarkers	A042, B051
bioPROTAC	B045, PR010
Bispecific ADC	A006
Bispecific ADC, Ovrian cancer, Folate Receptor	A012
bispecific NK cell engager	B059
blood brain barrier	B084, PR002
brain metastasis	B075
breast cancer	A066, B001, B080
Breast cancer	B009, B048, PR013
Breast Cancer	B053, B071
Breast Cancer	A013
breast, pancreatic, head	A080
butyrylcholinesterase	B038

C



AACR DRUG DISCOVERY AND DEVELOPMENT (AACR D3)

July 21-24, 2026 | Boston, MA

AACR
American Association
for Cancer Research*

25090336

Cancer therapeutics	A074
CAN020	A014
Cancer diagnosis and prognosis	A050
Cancer metabolism	B089
Cancer screening	A036
cancer stem cell	A078
Cancer Stem Cells	B071
Cancer stem cells (CSCs), Cloperastine, patient-derived orthotropic model	A084
cancer therapeutics	A060
cancer vaccine	B098
Cancer-targeting	A019
CAR engineering	B061
catalytic TOP2 inhibitor	A072
CBFB::MYH11	B079
CCNE1-amplification	A059
CD3 T-cell engager	A020
CD33, TRAIL-R2, TNFRSF10	A018
CD44v9	A013
CD79b/CD20	A006
CDK1	B009
CDK4/6 resistance	B048,PR013
Cell cycle arrest	B023
cell lineage reprogramming	B014
Cell Signaling	B052
Cell Therapies	B056,PR009
Cell-binding, predictive models, hit discovery	A033
Cell-SELEX, Deep learning Model, Aptamer	A033
checkpoint	B059
checkpoint inhibitors	B021
“Chemocentric” rational discovery	A054
chemoresistance	B086
Chemoresistance	A007
Chk1	A045
Chk2	A045
chordoma	A071
Chromatin Accessibility	B011



AACR DRUG DISCOVERY AND DEVELOPMENT (AACR D3)

July 21-24, 2026 | Boston, MA

AACR
American Association
for Cancer Research*

25090336

chromatin instability	B037
CIN	B070
CISH	B049
Cisplatin	B024
CLDN18.2 · Pancreatic Adenocarcinoma · KRAS	A046
clear cell renal cell carcinoma	B082
clinical	B042
CNS-targeting	A019
colorectal cancer	B098
Colorectal cancer	B091
Colorectal Cancer	A037, A047
Combination Therapy	A068
comparative effectiveness	A030, PR006
Computational Drug Discovery	A038
computer-aided drug design	A072
Consortia	A056
Contribution of Effect	B008
costimulation	B021
COX-2	A069, A075
CRC	B042
CRISPR	B093
CRISPR–Cas9	A061, A063, A064
CRISPR–Cas9, P53 gene, isoforms p53 protein	B019
ctDNA	A056
Cyclin E1	B044, PR003
Cyclin T1	B045, PR010

D

DAC	A004
dCBP-30, CBP/p300, Degradar	B047
Deep Learning	A040
degrader	IA05, IA06, A016, A053, B049
dendritic cells	B021
Developed Diagnostic Method	A092
digital twins	A026
disease biology, pathway, oncology	A022
Disulfidptosis	B027



AACR DRUG DISCOVERY AND DEVELOPMENT (AACR D3)

July 21-24, 2026 | Boston, MA

AACR
American Association
for Cancer Research*

25090336

DNA damage	B037
DNA damage response	A060
DNA damage response (DDR)	A062
DNA damaging agent	B035
DNA, Resistance, PARP	A080
DNA-based therapeutics	A019
DNA-damage response	A067
DNA repair	IA03
Doxorubicin	A051
Drug Delivery	A052, A074, A076
Drug development	IA07, A023, B029
drug discovery	A071
drug repurposing	A029, A032, B004
Drug resistance	A067, B001, B002
drug-resistant clones	B003
Drugs Adverse Events	A027
dsRNA	A042
Dual payload ADC, CDK7 inhibitor, TOP1 inhibitor	A009
Dual-payload ADC	A067
E	
Early detection	A036
EGFR	B078
EGFR signaling	B084, PR002
EGFR treatment	B006
EGFR-mutant	B050
ELF3	B007, PR001
Endometriosis	A044
Endpoints	B033
Enhertu, ILD, Antibody Drug Conjugates	A001
Enzalutamide-resistance	B004
EpCAM	A050
Epigenetic	A065
Epigenetics	B009, B010, B013
epithelial malignancy	A078
ERBB2 mutations	A008
ERG transcription factor	B094



AACR DRUG DISCOVERY AND DEVELOPMENT (AACR D3)

July 21-24, 2026 | Boston, MA

AACR
American Association
for Cancer Research*

25090336

ESE3/EHF transcription factor	B014
Essential thrombocythemia	A058
estrogen receptor alpha	B028
Evexomostat	B031
Ewing Sarcoma	IA03
Ex vivo profiling	B057
Experimental and Molecular Therapeutics	A038

F

Fentanyl	B030
Ferroptosis	A085
ferroptosis vulnerability	B081
FFPE	B012
Fiber-seq	B011
Fibroblasts	A088
first-in-class	B046,PR011
FLAURA , real-world progression-free survival (rwPFS) , first-line osimertinib	A057
FOLR1/MSLN	A005,PR008
foundation model	A030,PR006
Foundation Model, AI, machine learning	A034
Fructose	B095

G

Gastrointestinal cancers	B024
gene therapy	B017, B058
Genetic Interactions	B093
GLI	A086
Glioblastoma	A040, A085, B078, B084,PR002
Glioblastoma Multiforme	A039
GLUT5	B095
Glycoproteins	A041
GPCR-Neu1 signaling	B030
GPR68	A085
GUCY2C	B098

H



AACR DRUG DISCOVERY AND DEVELOPMENT (AACR D3)

July 21-24, 2026 | Boston, MA

AACR
American Association
for Cancer Research*

25090336

HDAC11 inhibition	A024
HDAC6	B088
Head and Neck Squamous Cell Carcinoma	A035
Hedgehog	A086
Hematology	A006
Hematotoxicity	A070,PR007
Heme, TP53, Ven	A018
hepatocellular carcinoma	B076
Hepatocellular Carcinoma	B087
Hepatocellular carcinoma (HCC)	B060
HER2+ breast cancer	A088
HER2-independent payload release	A011
HER2-negative breast cancer	A008
HGSOC	A059
High-throughput screening (HTS)	B032
Histone acetyltransferase, HAT, Multiple myeloma	B047
Hormone Receptor Positive Metastatic Breast Cancer	A090
Hydrogel Delivery	B016
I	
IAP antagonist	A078
IDH1 mutation	B027
IDH-mutant gliomas	B083,PR012
IL-12	B058
IL-15 superagonist	B017
Imatinib resistance	A092
Immune Checkpoint Inhibitor	B008
Immune Checkpoints	A041
immune trafficking	B066
Immunogenic cell death	B067
Immunohistochemistry	B023
Immuno-oncology	A042
immunotherapy	A021
Immunotherapy	A034, A048, B013, B056,PR009
Induced Proximity	B040
Inflammatory Breast Cancer	A041
Inhibitor	B088



AACR DRUG DISCOVERY AND DEVELOPMENT (AACR D3)

July 21-24, 2026 | Boston, MA

AACR
American Association
for Cancer Research*

25090336

Innate T cell immunotherapy.	B060
In-silico virtual trial	A026
Intracellular minibody	B094
intratumor	A055
Intratumor heterogeneity	B002
inverse probability of treatment weighting (IPTW) ,average treatment effect on the treated (ATT) ,external control arm / synthetic control	A057
Irisin	A075
J	
JAB-BX600	A015,PR005
JAK-STAT signaling	A091
K	
KAT6A, Next generation inhibitors, oncology	A070,PR007
KDM6	B083,PR012
KIF18A	B070
kinase	A053
KMT2A-rearranged	B022
KRAS	IA05, IA06, A029
KRAS G12D	A015,PR005
KRASi Resistance	A068
KRASQ61, Gastrointestinal malignancies	B036
L	
Laboratory automation	B032
large language models (LLM)	A031
LDHA inhibition	B080
lenvatinib	B064
LGR4/5/6, RSPO	A012
LILRB4	A004
Lipid nanoparticles	B097
LSD1, HNSCC resistance,	B055
Lung Adenocarcinoma	A083
lung cancer	A021
Lung cancer	A065



AACR DRUG DISCOVERY AND DEVELOPMENT (AACR D3)

July 21-24, 2026 | Boston, MA

AACR
American Association
for Cancer Research*

25090336

lymphoma	B049
Lysosome	B073
lysyl oxidase	B081
lysyl oxidase	B082
M	
machine learning	A026, B026
Machine learning	B025
Machine Learning	A035
machine learning protein binding	A024
Malic enzyme	B089
MAPK/ERK signaling	B007,PR001
mass spectrometry	B051
Mass Spectrometry	B052
MBD4, Replication stress	B092
MCL1	B015
Mechanisms	B025
medulloblastoma	A066
Melanoma	A011
Menin	B022
MET, AXL	B087
METAP2	B031
metastasis	B038
Metastasis	A069
MGD	B044,PR003
MHC-I	B055
microdevice	A055
microdose	A055
Microenvironment-mediated drug resistance	A091
Microfluidics	B032
Microfluidics mRNA cancer vaccines	B097
miR-100	A065
Modeling	B088
Molecular docking	A075
molecular glue	A053
Molecular glue	A054
Molecular Glue	B043, B096



AACR DRUG DISCOVERY AND DEVELOPMENT (AACR D3)

July 21-24, 2026 | Boston, MA

AACR
American Association
for Cancer Research*

25090336

Mono-ADP-Ribosyltransferase 1 (ART1)	A047
Monoclonal Antibody Therapy	A047
mRNA based strategy	B094
mRNA cancer vaccines	B097
mRNA-Based Therapy	B014
Mucosal-associated invariant T (MAIT) cell	B060
multiplexed screening	B026
multispecifics developability	A020
Multi-target therapy	A040
mutant breast cancer	B028
myelodysplastic neoplasms	B085
Myelofibrosis	A058
myeloid	B064
N	
Nanomedicine	A051
Nanoparticle	A073
Nanoparticles	B016
Natural killer T (NKT) cell	B061
Near-linkerless PROTAC, Enhancer, Lysine acetyltransferase	B047
Neoadjuvant Chemotherapy	A087
Neoantigen vaccine	A028,PR004
Network pharmacology	A081
Neuroimmune drug discovery	A044
Neurotoxic Adverse Side Effects	B020
NIR	A051
NK cell therapy	A021
Noncanonical Amino Acids, Biologics	B062
Noninvasive biomarker	B053
Non-small cell lung cancer	B006, B050
non-small cell lung cancer (NSCLC)	A031
Notch	B086
NSCLC	A025
O	
oncogenic protein–protein interactions	A049
Oncolytic virotherapy	A048



AACR DRUG DISCOVERY AND DEVELOPMENT (AACR D3)

July 21-24, 2026 | Boston, MA

AACR
American Association
for Cancer Research*

25090336

oncometabolite	A060
Organoid	B043
Organoids	A002
Ovarian cancer	B044,PR003
Ovarian Cancer	A005,PR008, B070, B073
P	
P53 gene	A061, A063, A064
p53-MDM2	A049
paclitaxel	B067
Pan-cancer transcriptomics	A081
pancreas cancer	B064
Pancreatic cancer	B030, B036
pancreatic cancer	A089
pancreatic cancer interception	A029
Pan-RAS inhibitors	A089
Patient Engagement in Research	IA07
patient derived xenografts	B006
PDAC	B046,PR011
PD-L1	B039
PDX	A002
pediatric cancer	B013
Pediatric cancer	B010
Pediatric Cancer, Pediatric Oncology	A034
peptide-drug conjugate	B035
Peptide-Drug Delivery System	B016
Personalized therapy	A092
Pharmacodynamic biomarkers	B090
Pharmacodynamics	A076
pharmacoepidemiology	A032
Pharmacokinetics	A016
Phosphoproteomics	B052
Physics-Informed Neural Networks	A039
Phytochemical drug discovery	A081
PKC inhibitors	B003
PKMYT1 inhibitor	A059
Platinum resistance	A062



AACR DRUG DISCOVERY AND DEVELOPMENT (AACR D3)

July 21-24, 2026 | Boston, MA

AACR
American Association
for Cancer Research*

25090336

Polycomb repressive complex	B010
Polymer drug conjugate	A073
Polymer-stabilised lipid nanodiscs	A074
Polyoxyl 35 castor oil	B020
Precision medicine	A090
prevention	B075
Prodrug	A052
prostate cancer	B031
Prostate cancer	B002
Prostate Cancer	B004, B077, B096
Prostatic neoplasms	A048
PROTAC	IA05, B041, B043, B048, PR013
Protein Therapeutics	A049
proteogenomics	A031
proteomics	B051
PSMA radioligand therapy	B054
Punica granatum var. pleniflora	A037
Q	
QP101, HER2, T-DXd resistance	A009
R	
Raman molecular histology	B090
rare cancer	A023
Rare Disease	A043
RAS	B005
RedTail EEV	B018
refractory	B059
Registry	A058
Regulatory B cells	B065
Replication stress	B083, PR012
Residual Disease Therapy	A039
resistance	A089
Resistance	B005, B025
Resistant Breast Cancer	A087
Resistant Cell panel	A068
Response prediction	B057



AACR DRUG DISCOVERY AND DEVELOPMENT (AACR D3)

July 21-24, 2026 | Boston, MA

AACR
American Association
for Cancer Research*

25090336

RIPTAC	B040
RNA interference	B015
RNA sequencing	B036
RNAPII	B012
RSK	B065
RWE	A025
S	
sarcoma	B034
scFv stabilization	A020
SCLC	A010
Selectivity, safety, breast cancer	A070,PR007
SERD resistance	B007,PR001
Serine Synthesis Pathway-Directed Therapies	B053
SERTI	B039
Single guide RNA	A061, A063, A064, B019
Single-cell transcriptomics	A044
Small Cell Lung Cancer	B056,PR009
small molecule	B075
small molecule inhibitor	B086
Small molecule inhibitor	B072
Small molecule kinase inhibitor	B085
Small-molecule therapy	B079
SMARCA2/4	A004
Solid tumor	B018
Spatial Biology	A076
Spatial metabolomics	B090
Spatial Transcriptomics	A083
sphingolipid-derived paclitaxel	B068
splicing factor	B074
stanniocalcin 1	B067
STAT3	B095
Structure-based drug design	B089
Sub-Saharan Africa	A027
synergy	A077
Synthetic Biology, Living Therapeutics	B062
synthetic control arms	A030,PR006



AACR DRUG DISCOVERY AND DEVELOPMENT (AACR D3)

July 21-24, 2026 | Boston, MA

AACR
American Association
for Cancer Research*

25090336

Synthetic Genomics, Genetic Code Engineering	B062
Synthetic Lethality	IA03, B091, B093
Synthetic lethality, Biomarker, Pharmacogenomics	B092
Systems Biology and Therapeutics	A038
T	
T cell Cytotoxicity	B022
T cell specificity	A028,PR004
TACC3	B041
Tamoxifen derivative	B001
Target Discovery	A043, B050
Target Identification	A083
Target trial emulation (TTE) , InfinityAI Data Library, EGFR-mutant NSCLC	A057
Targeted degradation	B039
Targeted drug delivery	A073
targeted protein degradation	B026, B042, B046,PR011
targeted protein acetylation	IA01
targeted protein degradation	IA01, A054
targeted protein stabilization	IA01
targeted therapy	B035
taxanes	B041
TBL1	B069
TCR-T therapy	A028,PR004
tegavivint	B069
Telomerase	B029
TFRC	A010
therapeutic resistance	B082
Therapy Resistance	B077
Therapy-Induced Senescence	A007
Thioredoxin reductase 1	B027
TME	B058
TNBC	A077, B081
tocilizumab	B034
Topo Isomerase 1 inhibitor-based ADCs, Trastuzumab, HER- 2 positive breast cancers, Interstitial Lung Disease	A001
TP receptor	A069



AACR DRUG DISCOVERY AND DEVELOPMENT (AACR D3)

July 21-24, 2026 | Boston, MA

AACR
American Association
for Cancer Research*

25090336

TR β agonist	B071
transactivation domain	IA02
Transcription	B012
Transcription elongation	B045,PR010
Transcription Factors	A071, B011, B096
Transcriptional repression	B028
Transcriptomics	A043, B020
transcriptome-selective pharmacology	IA02
Trastuzumab deruxtecan (T-DXd)	A008
Trial Design	IA07, B033
TRIB2, Enzalutamide, Resistance, Lineage plasticity, Neuroendocrine, Prostate Cancer	A079
Triple negative breast cancer, Bispecific ADC, MDSC depletion	A017
Tri-specific ADC	A005,PR008
Trop2	A014
TROP2 TCE	B018
TROP2, CD33, MMAE	A017
Tumor interstitial fluid	A050
Tumor Microenvironment	A088
tumor microenvironment (TME)	B066
Tumor microenvironment, Immune modulation, TOPO	A017
tumor penetration	B068
Tumor-on-chip	B066
Tumour microenvironment	B087
U	
U2AF1	B074
USP10 inhibition	A062
USP22, Treg, FOXP3, Genome editing	B063
uveal melanoma	B003, B038
V	
vaccinia virus EEV systemic	B017
Virotherapy	B024
Vitamin D3	A087



AACR DRUG DISCOVERY AND DEVELOPMENT (AACR D3)

July 21-24, 2026 | Boston, MA

AACR
American Association
for Cancer Research*

25090336

W

Warburg effect	B080
Wee1	A045
Wnt signaling	B069
WNT, heterogeneous	A012

X

There were no keywords in this range.

Y

There were no keywords in this range.

Z

There were no keywords in this range.